The diagnostic accuracy of 18F-FDG-PET (fluoro-2-deoxyglucose–positron emission
tomography) remains questionable for primary hepatocellular carcinoma (HCC) but seems …

Positron emission tomography (PET) imaging using 2-deoxy-2-[F-18] fluoro-D-glucose
(FDG) has proven valuable in the diagnosis, staging and restaging for many cancers …

Purpose: F-18 fluorodeoxyglucose (F-18 FDG) positron emission tomography
(PET)/computed tomography (CT) alone has limited sensitivity for the diagnosis of …

Background & Aims Hepatocellular carcinoma (HCC) staging according to the Barcelona
Clinical Liver Cancer (BCLC) classification is based on conventional imaging. The aim of …

Abstract 18 F-Fluoro-deoxyglucose (FDG) PET/CT can be used to monitor the biological
behavior of hepatocellular carcinoma (HCC). Baseline PET/CT has prognostic value in HCC …

Hepatocellular carcinomas (HCC) are the fifth most common cancer and are rapidly fatal in
almost all cases, with survival generally less than 1 year from diagnosis. F-18 FDG …

The aim of this study was to evaluate 18F-fluoroethylcholine PET/CT as a metabolic imaging
technique for the assessment of treatment response to 90Y radioembolization in patients …

Background/Aims: 18F-fluorodeoxyglucose uptake allows estimation of glucose metabolism
by tumor cells using positron emission tomography (PET). We evaluated the role of PET …

Accurate detection of hepatocellular carcinoma (HCC) foci in the liver and at the whole-body
level has a significant impact on patient management. Functional whole-body imaging by …

Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third most
frequent cause of cancer-related death. A growing number of local and systemic therapies …